1 Title: Utilization of CoRDS Registry to Monitor Quality of Life in Patients with VCP

2 Multisystem Proteinopathy

- 3
- 4 Eiman Abdoalsadig^{1,2*}, Merwa Hamid^{1*}, Allison Peck^{3*}, Leepakshi Johar^{1,4}, Virginia Kimonis^{1,5,6}
- 5 * Contributed equally to the work and should be considered co-first authors

6 **Affiliations:**

- ⁷ ¹Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California
- 8 Irvine Medical Center, CA, USA
- 9 ²Yale School of Public Health, CT, USA
- 10 ³Cure VCP Disease, Inc., Warner Robins, Georgia
- ⁴College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona,
- 12 CA, USA
- 13 ⁵Department of Neurology, University of California Irvine Medical Center, CA, USA
- ⁶Department of Pathology, University of California Irvine Medical Center, CA, USA

15 **Correspondence:**

- 16 Virginia Kimonis, MD. MRCP
- 17 Professor, Department of Pediatrics
- 18 Division of Genetics and Genomic Medicine
- 19 University of California-Irvine
- 20 Lab and FEDEX: Hewitt Hall, Rm 2038,
- 21 Health Sciences Rd., Irvine CA 92697
- 22 Tel: (949) 824-0571
- 23 vkimonis@hs.uci.edu

24 Abstract

25 Background

26 VCP disease, also known as multisystem proteinopathy (MSP1), is a rare, autosomal dominant,

- 27 adult-onset, neuromuscular disease that is caused by variants in the valosin-containing protein
- 28 (VCP) gene. VCP disease may exhibit one or more of the following primary features: Inclusion
- 29 Body Myopathy (IBM), Paget's disease of bone (PDB), Frontotemporal Dementia (IBMPFD),
- 30 and Amyotrophic Lateral Sclerosis (ALS). Due to its progressive nature, death normally occurs

31 in their sixties due to respiratory and cardiac failure. The purpose of this study is to utilize the

32 Cure VCP Disease patient registry hosted by the Coordination of Rare Diseases at Sanford

33 (CoRDS) to conduct a prospective natural history study.

34 Methods

35 Seventy-nine participants enrolled in the patient registry and answered demographic, VCP

36 variant type, Patient-Reported Outcome Measures (PROMs), and Quality of Life (QOL)

37 questionnaires over the course of three years. We additionally investigated if any sex differences

38 existed and if genotype-phenotype correlations affected the rate of progression of the varying

39 clinical manifestations.

40 **Results**

41 Overall, participants' mobility declined significantly as the disease progressed. Participants

42 reported a 0.6% decline in upper extremity function, 1.2% decline in lower extremity function,

43 and 0.3% decline in cognitive function per year of age. Furthermore, participants reported a 1.6%

44 decline in upper and lower extremity function and a 0.1% decline in cognitive function per year

45 of disease duration. The highest PROMs correlations between overall health and lower extremity

46 function, upper extremity function, fatigue, and the ability to perform vigorous activities.

- 47 Genotype-phenotype correlations revealed no significant differences except for the absense of
- 48 PDB in the *p.Arg159Cys* group.
- 49 Conclusion
- 50 The VCP CoRDS Registry was found to be a valuable tool for monitoring the QOL in patients
- 51 with VCP disease and capturing patient perspectives for future clinical trials.

52 Keywords

- 53 VCP, Inclusion Body Myopathy, Paget's Disease of Bone, Frontotemporal Dementia (IBMPFD),
- 54 and Amyotrophic Lateral Sclerosis (ALS), multisystem proteinopathy, Patient-Reported
- 55 Outcome Measures (PROMs), and Quality of Life (QOL)
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- -----
- 69

70 Background

71 Valosin-containing protein (VCP) disease, otherwise known as inclusion body myopathy (IBM) 72 associated with Paget disease of the bone (PDB) and frontotemporal dementia (FTD) (frequently 73 used acronym, IBMPFD), or more recently, multi-system proteinopathy type 1 (MSP1), is a 74 progressive, debilitating, predominantly autosomal dominant genetic condition, which can affect 75 the muscle, bone, and/or brain. The condition was first reported in 2000 [1] as a new familial 76 disorder of limb-girdle type of muscle weakness and skeletal disorganization due to PDB, which 77 was later identified to be due to heterozygous missense variants in the VCP gene mapped to 78 chromosomal location 9p211-p12 [2-4]. The VCP (p97) gene encodes for an abundant cytosolic 79 AAA ATPase with multiple cellular functions. It is involved in the ubiquitin-proteasome system 80 (UPS), the endoplasmic reticulum-associated protein degradation (ERAD), DNA endosomal 81 sorting, cell cycle regulation, and autophagy [5-8]. To date, more than 80 missense variants 82 associated with VCP disease have been identified [6]. At the cellular level, variants lead to the 83 increased enzymatic activity of AAA ATPase reflecting a gain of function mechanism which 84 dysregulates protein degradation through ERAD and/or UPS resulting in activation of the ER 85 stress response [7] resulting in a global disturbance of protein folding [5].

86

Al-Obeidi et al. (2018), reported myopathy (typically IBM) in 90% of studied individuals with
VCP disease, PDB in 42%, and FTD in 30% [8]. IBM manifests as progressive muscle
weakness, difficulty in raising the arms and walking upstairs, and atrophy of the muscles of the
pelvis and shoulder girdle. Histologically, IBM is characterized by rimmed vacuoles containing
protein aggregates of TDP-43 [9]. PDB often consists of an increase in osteoclastic activity
resulting in disorganized bone structure and bone weakness, resulting in fractures and localized

93	arthritis [10]. VCP gene variants have also been reported to cause ALS in 10%, Parkinson's
94	disease in 5%, and cardiomyopathy in up to 27% of patients [8] [11-14]. FTD affects speech
95	production and recall, comprehension, and personality [13-14]. Owing to the progressive nature
96	of the disorder, death usually occurs prematurely in the 60s due to respiratory and cardiac failure
97	[8].
98	
99	Currently, while bisphosphonates can be effectively used to manage PDB, there are no
100	treatments that can modify the progression of VCP disease-associated myopathy or FTD [6].
101	Medical management includes physical therapy, weight control, respiratory aids, and mechanical
102	aids such as walkers or wheelchairs [6]. Patients are also recommended to receive regular
103	surveillance to monitor cardiac, bone, lung, and neurologic function following diagnosis [6].
104	
105	Even though VCP disease is now reported in several hundred patients across the globe, there are
106	limited studies investigating how VCP disease affects the quality of life (QOL) of patients over
107	time. We therefore planned to analyze patient reported data to ascertain the prevalence, age of
108	onset of different manifestations, and track the progression of mobility, cognitive function, and
109	pain levels in patients with VCP disease.
110	
111	Methods
112	Cure VCP Disease, Inc., a patient advocacy group established to unite patients and researchers to
113	advance treatments and cures for VCP disease, collaborated with the Coordination of Rare
114	Diseases at Sanford (CoRDS), a centralized international patient registry for rare diseases, to
115	host a patient registry (VCP CoRDS Registry). The registry survey contains 143 unique

116 questions related to demographics, diagnosis, age of onset, symptoms, disease progression, pain, 117 and QOL. The registry participants are prompted to update survey responses annually. Thus, a 118 longitudinal natural history study over the course of up to three years was established to explore 119 the progression of QOL symptoms among VCP disease patients. Using data contained in the 120 registry, we conducted the following analyses: 1) progression of functional abilities, 2) quality of 121 life correlations, and 3) genotype-phenotype correlations. We compiled the genetic variant and 122 phenotype responses from the VCP CoRDS Registry for each participant to conduct a genotype-123 phenotype comparison for the specific VCP disease variant. We used Excel and SPSS to conduct 124 one sample t-tests with a 95% confidence interval for the statistical analysis in the genotype-125 phenotype comparison (IBM SPSS Statistics, Version 27). 126 127 For the progression of functional abilities analysis, we extracted from the VCP CoRDS registry, 128 the responses from three surveys developed by the National Institute of Neurological Disorders 129 and Stroke (NINDS): lower extremity function (Neuro-QOL Item Bank v 1.0 short form), upper 130 extremity function (Neuro-QOL Item Bank v 1.0 short form), and cognition function (Neuro-131 QOL Item Bank v 2.0 short form) [15]. Each Neuro-QoL survey consists of eight questions 132 developed to assess upper extremity function (such as their ability to turn a key in a lock, brush 133 teeth, write with a pen or pencil, open and close a zipper), lower extremity function, and 134 cognitive function, respectively. These patient-reported outcome measures (PROMS) have been 135 previously proven to be valuable tools to increase understanding of disease symptoms and 136 overall quality of life [16-17]. The 5-point Likert scale was applied in these responses to 137 understand the extent to which participants can perform specific daily functions where a score of 138 1 is defined as the inability to perform a task while a score of 5 is the ability to complete a task

139 without any difficulty. The total raw scores from the short forms were calculated for lower 140 extremity function, upper extremity function, and cognitive function. To analyze pain in this 141 population, we used the pain levels reported in the patient registry on a scale of 0-10 with 10 142 being the worst pain imaginable. Mild pain was defined as 0-3; moderate pain was 4-6; and 143 severe pain was 7 or higher on the pain scale. We then compared pain levels and progression of 144 pain between male and female participants by comparing their pain level with age as well as 145 disease duration. We applied a linear regression model to observe the progression in mobility, 146 cognitive function, and pain with age and disease duration. 147 148 Lastly, we analyzed the possible effect of disease progression, pain, and age on OOL. 149 Participants reported their QOL symptoms by answering five questions in the QOL section of the 150 VCP CoRDS Registry. We converted the participants' responses using a 5-point Likert scale 151 (where 1 represents poor QOL while 5 represents excellent QOL utilizing their latest responses), 152 in which those scores were added to a bar chart comparing the latest responses of symptomatic 153 and pre-symptomatic participants. Mobility and cognitive function were classified according to 154 the total raw scores provided by the Neuro-QOL surveys. We calculated the Spearman 155 correlation coefficients to evaluate if any correlations existed between each of the following nine 156 metrics through a correlation matrix: age, disease progression (lower extremity, upper extremity, 157 cognitive function, and pain), and QOL factors (vigorous activities, fatigue, general health, pain 158 interference, and depression). We classified correlations between these factors as strong (± 0.7 -159 1.0), moderate (\pm 0.4-0.6), and weak (\pm 0.0-0.3). We utilized the R program to generate a 160 visually informative heat map, offering a comprehensive depiction and comparison of the 161 various correlation coefficient magnitudes [R version 4.4.0 (Puppy Cup) prerelease versions].

162 **Results**

163	Demographic information was collected from the VCP CoRDS Registry (Table 1). Seventy-nine
164	participants [males (N=35, 44.3%), females (N=39, 49.4%), and five unreported sex (6.3%)]
165	contributed to this study and approximately 89% of the participants reported themselves as
166	'White' with 4% 'Asian', and 6% 'Mixed or Other'. The average age reported associated with
167	diagnosis of muscle weakness, PDB, and dementia was 42.3 years, 47.3 years, and 54.8 years,
168	respectively. Seventy-nine participants were registered from nine different countries (Figure 1).
169	Most of the participants were from the United States (N=59, 71%), followed by the United
170	Kingdom (N=5, 6%) and Australia (N=5, 6%). Four participants did not indicate their country of

171 submission.

Table 1. Demographic Data of Participants (* prevalence)

Total Participants (N=79)	Mean Age ± SD (years)	Range (years)				
Age at enrollment (N=77)	51.6 ± 11.8	21-77				
Age of symptomatic onset (N=57)	42.4 ±11.6	5-71				
Age at diagnosis (N=69)	46.8 ±11.5	17-73				
Age of onset of muscle weakness (N=60, 76%*)	42.3 ± 9.6	12-67				
Age at onset of Paget's disease (N=18, 23%*)	47.3 ± 9.4	30-68				
Age at onset of dementia (N=9, 11%*)	54.8 ± 16.3	25-71				
Participant Sex (N= M: F)	35:39	5-77				
Racial Categories	N (%)					
White	63 (89%)	21-73				
Asian	3 (4%)	50-67				
Black or African American	1 (1%)	54				
Mixed or Other	4 (6%)	27-77				
Ethnicity						
Hispanic or Latino	6 (10%)	56-62				
Non-Hispanic	54 (90%)	21-77				






Figure 1. Demographic Data of Participants by Country of Residence. Seventy-nine
participants from nine different countries participated in the study. Fifty-nine participants (75%)
registered in the United States. One participant (1%) did not indicate country of submission.

176 Of the total number of participants registered, nine participants were pre-symptomatic (Figure 177 S1). A pre-symptomatic participant is defined as someone who has a variant on the VCP gene 178 but has neither been diagnosed with nor experienced a VCP-related clinical symptom. Sixty-six 179 (84%) participants were symptomatic, meaning the participant either reported a clinical diagnosis 180 or VCP-related clinical symptoms in the registry (Figure 2). Three participants indicated "other" 181 under physical diagnosis, however, did not specify their comorbidities. The status of four 182 participants is unknown. Out of the 62 symptomatic participants that reported a phenotype 183 diagnosis, the most common clinical feature reported was myopathy (N=52, 83.9%); notably, of 184 these patients, twenty participants (32.3%) reported isolated myopathy and thirteen participants

185	(21.0%) reported both myopathy and PDB (Figure 2). The second most common physical
186	diagnosis was PDB (N=18, 29.0%). In addition, nine participants reported FTD (14.5%), six
187	participants reported peripheral neuropathy (9.7%), nine participants reported cataracts (14.5%),
188	four participants reported cardiomyopathy (6.5%), three participants reported ALS (4.8%), and
189	one participant reported Parkinson's disease (1.6%). Sixty-seven participants reported their mean
190	age of diagnosis for VCP disease as 49 years (range 23-73). Of the symptomatic group, twelve
191	participants (17.9%) were diagnosed between the ages of 31-40 years, twenty-one (31.3%) were
192	diagnosed between the ages of 41 years and 50 years, and twenty participants (30%) were
193	diagnosed between the ages of 51 years and 60 years. A large majority of participants reported
194	symptom-onset during adulthood; however, one participant reported having symptoms starting at
195	the age of 12 years while another participant was pre-symptomatically diagnosed at the age of 17
196	years (Figure S2). Among the 56 participants who reported their age of first symptom onset, the
197	most common age range was between 31-40 years (N=20, 36%), closely followed by 41-50 years
198	(N=17, 30%). In this cohort, the average time from symptom onset to establishment of the
199	diagnosis was 6.8 years with the longest duration of 29 years (Figure S2).



200 Supplemental Figure 1. Quality of Life - A Comparison of Pre-Symptomatic vs.



202 symptomatic (green, N=66) participants when asked five QOL questions was conducted. (a)

203 Participants' responses when asked about their general health. (b) Participants' responses when

- asked if their health limits them in doing vigorous activities. (c) Participants' responses when
- asked if they feel depressed. (d) Participants' responses when asked how often they feel tired. (e)
- 206 Participants' responses when asked how much pain interfered with their enjoyment of life.







Figure 2. Venn Diagram of Physician-Confirmed Diagnoses in 66 Participants. Each circle represents a different physical diagnosis. Areas where the circles overlap are defined as the participant reporting having multiple diagnoses. One participant (not illustrated) who reported "other" was diagnosed with Parkinsonism and ataxia. The status of four participants (not displayed) is unknown. a: Indicated other in addition to provided physical diagnoses. b: One participant also reported cataracts. c: One participant also reported dementia. d: One participant also reported Parkinson's disease. e: One participant also reported peripheral neuropathy.



Supplemental Figure 2. Demographics. (a) Age of diagnosis of participants with VCP disease
(N=67). (b) Age of first symptom onset in VCP disease participants (N=56). Each slice
represents a specific age range.

218

219 Genotype-Phenotype Comparison

220 The genotype-phenotype analysis of this cohort revealed phenotypic diversity in VCP disease in

relation to the variant group and the corresponding clinical features reported (Table 2, S1).

Among the 49 participants (mean age 52.5 years) who reported their VCP variant, 17 (35%)

reported the *p.Arg155His*, *c.464G>A*, variant, making this the most prevalent variant in this

cohort (Table 2, S1). Not surprisingly, all the phenotypes were represented in this *p.Arg155His*

225 cohort (myopathy, PDB, dementia, ALS, peripheral neuropathy, Parkinson's disease, and

cataracts); Parkinson's disease was reported by only one participant in the R155H variant group

in 5.6% (2%), ALS was only reported by two (4.1%) participants with *p.Arg155His* variant and

228 was not reported in the other variant groups. The earliest reported age of onset was by a 27-year-

229 old participant with myopathy and peripheral neuropathy with the *p.Arg155His*, *c.464G>A*

230 variant (Table S1). The second most prevalent variant group with 8 participants was the

231 *p.Arg155Cys, c.463C>T* group. Among all the variant groups, myopathy was identified in 36

232 participants [73.5%, 43.1 \pm 8.8 years], making it the most common phenotype. The only possible

233 notable genotype-phenotype correlations identified was the absence of PDB in the *p.Arg159Cys*,

234 c.475C > T variant group.

Variant group	N=49 (%)
p.Arg155His, c.464G>A	18 (36.2%)
p.Arg155Cys, c.463C>T	6 (17.0%)
p.Arg159His, c.476G>A	5 (6.4%)
p.Arg93Cys, c.277C>T	3 (8.5%)
p.Arg159Cys, c.475C>T	4 (8.5%) ^b
p.Arg191Gln, c.572G>A	3 (6.4%)
p.Leu198, c.Trp 593T>G	2 (4.3%)
p.Gly97Glu, c.290G>A	1 (2.1%)
p.Ile369Thr, c.1106T>C	1 (2.1%)
p.Arg95Gly, c.283C>G	1 (2.1%)
p.Asn387Thr, c.1160A>C	1 (2.1%)
p.Gly128Ala, c.383G>C	1 (2.1%)
p.Gly782Ala, c.2345G>C	1 (2.1%)

Table 2. VCP gene variants in current cohort

235

236

237 Supplemental Table 1: Genotype—phenotype comparison data of clinical features

238 symptomatic patients in different variant groups. (Please see appendix)

Abbreviations: *N*= sample number, *NA* = not applicable; No participants reported to have the

240 corresponding symptoms in the phenotype categories.

241

242 **Progression of Functional Abilities**

243 Upper and Lower Extremity Function

244 We assessed the mobility of the sixty-seven participants who completed all the questions in the

245 Neuro-QoL upper and lower extremity function surveys by analyzing the responses separately.

246 Examples of PROM questions pertaining to upper extremity function include the ability to turn a

247 key in a lock, brush teeth, write with a pen or pencil, open and close a zipper, etc. Affected

participants showed an overall decline of 0.58% in upper extremity function with every 1-year increase of age (slope=-0.38, R^2 =0.23) (Figure 3a). Participants also displayed an overall decline of -1.57% in upper extremity function for every 1 year of disease progression (slope=-0.63, R^2 =0.32) (Figure 3b). Similar trends were seen in males and females with age (p=0.45) and disease duration (p=0.57).





Figure 3. Upper Extremity Function Progression. A scatter plot was created to illustrate the correlations between (a) age and (b) disease duration relative to the total reported raw score for upper extremity function. The solid lines indicate progression within a singular participant over time for data with multiple submissions whereas the dashed lines indicate overall progression in males (blue) and females (pink) using the latest submission. Both male (blue squares) and female participants (pink circles) showed a rapid decline in their overall mobility with increasing age and also disease duration.

260

Both sexes exhibited similar trends in lower extremity function with increasing age with an overall decline of 1.19%, (Figure 4a). Participants reported an overall decline in lower extremity function as their disease progressed (slope=-0.64, R^2 =0.27) (Figure 4b). Females demonstrated a more rapid decline (slope=-0.66, R^2 =0.29) than males (slope=-0.59, R^2 =0.25). Participants also

rated their upper extremity function by answering PROM questions such as their ability to run



errands, get in and out of a car, step up and down curbs, and walk for at least 15 minutes.


Figure 4. Lower Extremity Function Progression. A scatter plot was created to illustrate the correlations between (a) age and (b) disease duration relative to the total reported raw score for lower extremity function. The solid lines indicate progression within a singular participant over time for data with multiple submissions whereas the dashed lines indicate overall progression in males (blue) and females (pink) using the latest submission. Both male (blue squares) and female participants (pink circles) showed a rapid decline in their overall mobility with increasing age and disease duration.


274

275 *Cognitive Function*

276 Next, we assessed the cognitive function of the seventy participants who completed the Neuro-277 QoL cognitive function survey. PROM questions to assess cognitive function include ability to perform specific tasks such as reading and following complex instructions, concentrating, and 278 279 paying attention. Similar to the technique used in the calculation of functional ability, we 280 calculated the total raw scores and then created a scatter plot to show the correlation with age in 281 years (Figure 5). Both males (N=33) and females (N=37) displayed an overall gradual decline in 282 cognitive function, however females showed a slightly more rapid decline (slope=-0.18, 283 $R^2=0.06$) compared to males (slope=-0.06, $R^2=0.01$) (Figure 5a). Overall, there is no correlation

between cognitive function and disease duration for every year of age, regardless of sex





286 Figure 5. Cognitive Function Progression.

A scatter plot was created to illustrate the correlations between (**a**) age and (**b**) disease duration relative to the total reported raw score for cognitive function. The solid lines indicate progression within a singular participant over time for data with multiple submissions whereas the dashed lines indicate overall progression in males (blue) and females (pink) using the latest submitted value. Both male (blue squares) and female participants (pink circles) showed a decline in their overall cognitive abilities with increasing age whereas little to no decline with increasing disease duration.

294

295 Pain Level

Based on the overall pain scale, 13.0% of participants reported no pain, 38.2% reported mild

pain (pain score1-3), 35.3% reported moderate pain (pain score 4-6), and 13.2% reported severe

298 pain (pain score 7 or higher). Furthermore, 80.3% of symptomatic participants reported pain

sometimes, often, or always interferes with their enjoyment of life (Figure S2). Using the latest

300 participant data entries, we created a bar graph comparing the frequency of reported pain levels

301 between male (N=34) and female (N=38) participants (Figure 6). There was a wide distribution


in pain levels among participants, with 2 being the most frequent score for females (22.9%) and


303 3 being the most frequent score for males (24.2%), according to the latest submission.


304 Interestingly, females showed a gradual decrease in pain (slope=-0.03, R²=0.03), whereas males

- showed an increase in pain with increasing age (slope=0.08, R²=0.13) (Figure 7a). Most male
- 306 and female participants with multiple entries reported no change in pain, while some reported an

307 increase in pain.







313 Figure 7. Pain Level Progression. A scatter plot was generated to illustrate the correlations 314 between age (a) and disease duration (b) relative to the total reported raw score for pain. The 315 solid lines indicate progression within a singular participant over time for data with multiple 316 submissions whereas the dashed lines indicate overall progression in males (blue) and females 317 (pink) using the latest submission. Male participants (blue squares) showed an incline in their 318 overall pain levels with increasing age and disease duration whereas female participants (pink 319 circles) showed a decline in pain levels with increasing age but an increase in pain levels as the 320 disease progressed.

321

322 **Quality of Life**

323 **Quality of Life in Symptomatic Participants**

324 Seventy-five participants completed the five QOL survey questions in the VCP CoRDS Registry

325 (9 pre-symptomatic, 66 symptomatic) (Figure S2). Among symptomatic participants, 88%

- 326 (57/66) of symptomatic participants reported that their health often or always limits doing
- 327 vigorous activities, 76% (51/66) reported that they often or always felt tired, 55% (36/66)
- 328 reported fair or poor general health, 45% (29/66) reported that pain always or often interfered
- 329 with their enjoyment of life, and 29% (19/66) reported being always or often depressed. The

responses of pre-symptomatic patients are included in the graph for reference, but due to the lownumbers, a comparison was not calculated.

332

333 Quality of Life, Disease Progression, and Age Correlations:

334 Moderate positive correlations were found between vigorous activities and upper (0.57) and 335 lower (0.63) extremity function, suggesting that musculoskeletal health and functional ability 336 across different body areas for patients with VCP disease has a negative impact on the intensity 337 of physical exercise. Furthermore, the moderate positive correlation between pain interference 338 and fatigue (0.63) implies that as pain interference increases, there is a negative impact on the 339 enjoyment of life for individuals experiencing these symptoms. Depression and fatigue (0.46), 340 and pain interference and depression (0.41) also had positive correlation. This suggests that those 341 who often felt that pain interfered with their enjoyment of life also reported feeling depressed 342 and those who reported often having feelings of depression also reported greater feelings of 343 tiredness. This connected relationship emphasizes the concept that perceptions of pain 344 interference, feelings of depression, and tiredness are closely intertwined, highlighting the 345 complexity of these emotional and physical states VCP patients experience. Additionally, several 346 moderate positive correlations were found between overall general health and other factors: 347 lower extremity function (0.63), upper extremity function (0.46), fatigue (0.46), and vigorous 348 activities (0.46). Moderate negative correlations were found between pain level and fatigue (-349 (0.57), pain level and pain interference (-0.56), lower extremity function and age (-0.49), and 350 vigorous activities and age (-0.41) while all other correlations were weak. This analysis provided 351 a sophisticated understanding of the complex relationships among the factors under

investigation. These findings emphasize the significance of considering multiple perspectives ofVCP patients to improve affected individuals' overall well-being and quality of life.

354

355 When comparing age, disease progression and QOL factors, a strong correlation was discovered between lower extremity function and upper extremity function (0.85). Additionally, moderate 356 357 correlations were found between lower extremity function and vigorous activities (0.63). These 358 findings are consistent with the known progression of muscle disease in both the upper and lower 359 skeletal muscles. When analyzing patients' determination of their overall general health, lower 360 extremity function had the strongest correlation (0.63), with upper extremity function, vigorous 361 activities and fatigue also revealing a moderate correlation to overall general health (0.46 362 respectively). Loss of muscle function has a direct effect on a person's ability to complete daily 363 activities and participate in vigorous activities, so these findings are not surprising. Our data 364 revealed moderate correlations between age and lower extremity function as well as vigorous 365 activities, while pain, general health, cognition function, and fatigue showed weak correlations 366 with age.

367

368 Heat Map depicting Quality of Life correlations between key health factors.

We studied correlations between pain level, cognitive function, lower extremity, upper
extremity, general health, vigorous activities, pain interference, fatigue, depression factors that
were evaluated in the questionnaire. The larger and darker the circle around the correlation value,
the stronger the correlation between the two variables (Figure 8).

373

374	A patient's pain level displayed a moderate negative correlation to both fatigue (-0.57) and how
375	often pain interfered with their enjoyment of life (-0.56). In other words, as pain level increased,
376	a patient was more likely to report being tired and having pain interfere with their enjoyment of
377	life. Strong evidence of a relationship between pain and tiredness, and between pain interference
378	and depression. Interestingly, fatigue and pain interference have the same correlation to pain
379	level suggesting the significance of both pain and fatigue in the enjoyment of life. Moreover, a
380	significant percentage of VCP patients reported experiencing fatigue at high levels, with 76%
381	(51/66) reporting that they often or always felt tired and 88% (57/66) of symptomatic
382	participants reporting that their health often or always limits doing vigorous activities. A
383	correlation analysis between fatigue, pain inference, and depression further revealed a moderate
384	correlation between all three of these factors [pain inference and fatigue (0.63), fatigue and
385	depression (0.46), and pain inference and depression (0.41)].




Figure 8. Quality of Life. This is a representation of a heat map signifying the correlation between the first five variables, which were measured during the study. General Health, Vigorous Activities, Pain Interference, Tiredness, Depression were factors that were evaluated from our questionnaire. The scale on the right represents the direction and intensity of the correlation. The larger and darker the circle around the correlation value, the stronger the correlation between the two variables.

402

403 **Overall Summary of Findings:**

404 Among the 79 participants, myopathy was the most prevalent phenotype (84.0%), followed by 405 PDB (43.4%), FTD (12.9%), ALS (4.8%), and Parkinson's disease (1.6%). Regarding the 406 disease progression studies, participants revealed a significant decline of 0.6% in upper extremity 407 function, 1.2% in lower extremity function, and 0.3% in cognitive function per year of age. 408 Participants also revealed a 1.6% decline in upper and lower extremity function and a 0.1% 409 decline in cognitive function per year of disease duration. This study highlights the high 410 frequency of pain and the impact of fatigue on the quality-of-life aspects, such as depression and 411 enjoyment of life in this patient population. Interestingly, the strongest correlation concerning 412 patient reported general health was not age but lower extremity function. The c. 464G>A, 413 p.R155H VCP variant was reported as the most prevalent variant group with the highest number 414 of phenotypic characteristics. No obvious genotype-phenotype correlations for VCP disease 415 phenotypes were noted.

416

417

418

419 **Discussion**

420	Studying the natural history of a disease is important because it provides critical information on
421	how the disease affects a patient's daily life, understanding disease progression, which can thus
422	be useful in creating preventative interventions, and permits studying the effects of therapeutic
423	interventions. The inclusion of real-world evidence in the 21st Century Cures Act and the use of
424	PROMs in the FDA guidance in drug development elevates the need to evaluate natural history
425	from the patient's perspective early in the drug discovery process [17, 18].
426	
427	Influence of Genotype on Phenotype
428	Valosin-containing protein (VCP) variants can cause adult-onset proximal myopathy, which
429	leads to upper and lower extremity weakness, axial myopathy, scapular winging, PDB and
430	frontotemporal dementia (IBMPFD) [4, 19-21]. The most common phenotype was myopathy
431	with the mean age of onset of 43.1 years as previously reported [22], followed by PDB with an
432	average age of onset of 44.8 years. VCP has several functions: it is involved in cell division,
433	repairing DNA damage, membrane fusion, and reassembling structures in cells post-division. It
434	is also involved as an ATPase in autophagy and cell degradation, including ubiquitin-related
435	cellular processes [5]. The VCP enzyme consists of the N domain and D1 and D2 domains,
436	which are the ATPase modules. The D1 and D2 domains of VCP form a homohexamer in a
437	head-to-tail ring structure, which allows the N domain to undergo conformational changes when
438	ubiquitin-binding occurs. Missense variants in the VCP gene that cause IBMPFD can disrupt the
439	double-psi barrel (R95G), four-stranded beta-barrel (R155C, R155H, R155P), or the flexible

440 linker (R191Q). Most of the variants are in the N-terminal domain, which has the function of

441 binding cofactors and ubiquitylated proteins [4]. We reported 13 unique variants in this

cohort. The R155 codon is a mutational hotspot reported in 46% of the VCP variants reported in
our study; the most prevalent is R155H, followed by R155C, as reported previously [4, 21].
Based on our genotype-phenotype comparisons study, we did not observe any significant
correlations.

446

447 Disease Progression

448 A notable decline in mobility was detected in participants with VCP disease, exhibiting a 449 negative correlation with both advancing age and prolonged disease duration. The presence of 450 comorbidities such as myopathy, PDB, ALS, and Parkinson's disease further exacerbates the 451 decline in mobility seen in those with VCP disease. The variability in decline of mobility due to 452 VCP myopathy aligns with the documented progression pattern in limb-girdle muscular 453 dystrophy (LGMD), which could be characterized by a heterogeneous onset of muscle weakness 454 affecting the pelvic and shoulder girdles, typically manifesting in adolescence or early adulthood. 455 The progression of LGMD varies widely, with some patients experiencing rapid deterioration 456 while others show a slower decline [23, 24]. Variability in progression rate is similarly observed 457 in ALS, particularly among patients with SOD1 mutations. For instance, individuals harboring 458 the SOD1 A4V mutation often experience a more aggressive disease trajectory, with a median 459 survival of approximately 1.2 years, in contrast to the 6.8 years observed for other SOD1 460 mutations [25]. Studies emphasize the importance of early clinical markers, including changes in 461 functional scores and respiratory function, to elucidate disease trajectories and inform therapeutic 462 strategies. These insights highlight the necessity of an integrated approach to the clinical 463 management of VCP disease, addressing both the primary disorder and its associated co-464 morbidities to enhance patient outcomes and quality of life.

465 Overall, both male and female participants displayed slight cognitive impairments with age. This 466 is consistent with previous studies of families with patients who displayed cognitive impairments 467 at a mean age of 56 years [8]. Following a detailed investigation of the link between aging and 468 cognitive performance, our findings demonstrated a steady deterioration in cognitive function 469 with increasing age. Previous research confirms this by concluding a negative connection 470 between age and cognitive performance across a variety of activities, including memory, 471 processing speed, and executive functioning [26]. The research goes into neuroimaging studies, 472 which highlight structural and functional changes in the aging brain, notably in memory and 473 information processing areas [26]. According to another study, the aging brain experiences 474 complex interactions and changes that affect many cognitive processes other than memory and 475 information processing. Altogether, these investigations confirm a similar trend: an individual's 476 cognitive capacity tends to deteriorate with age. In addition to identifying potential treatment and 477 preventive methods to reduce age-related cognitive loss, it is critical to underline the importance 478 of multidisciplinary research in understanding the complex nature of cognitive aging [27].

479

480 Pain Implications

In analyzing the reported pain levels, males reported more pain with the progression of the disease (slope = 0.08 versus -0.03, p<0.01) with advancing age. In other studies, a multitude of factors, including biological, psychosocial, sex difference, have been proven to influence an individual's pain, and understanding these factors can serve as a vital foundation for individualized pain treatment plan [28]. Pain is a common and underappreciated manifestation of VCP disease and can result from comorbidities such as PDB, which typically affects the lumbar spine, hips, pelvis and skull [25]. It is important to investigate the presence of PDB to reduce the

488 additional burden since it is readily treatable with bisphosphonates. Interestingly in this cohort, 489 symptomatic VCP participants with PDB did not report a higher level of pain when compared to 490 symptomatic VCP participants without PDB (average pain score of 3.2/10, 4.1/10, respectively). 491 These results may suggest that patients may have undiagnosed PDB or that some patients with PDB may be receiving treatment to address their pain. We further analyzed similarities among 492 493 patients who reported high levels of pain, and the presence of myopathy was the only common 494 factor we discovered. Interestingly, a greater percentage of VCP participants without PDB 495 reported a moderate to high level of pain (4 or higher) when compared to VCP participants with 496 PDB (55% 26/45, 37% 6/16). These results suggest that PDB may not be the main source of pain 497 and that other disease-specific causes of pain exist in VCP disease, such as muscle pain or 498 neuropathy. Thus, these results indicate that the detection and treatment of an individual's pain 499 needs to be part of a VCP patient's clinical care plan; future studies are needed to determine the 500 causes of pain in VCP patients.

501

502 Sex Considerations

503 Other research studies indicate that males may have a more noticeable perception of decline in 504 physical activity as they are unable to reach their activity goals, and this perception of change 505 may explain the steeper reported decline in lower extremity function reported in males (slope=-506 0.52, R²=0.34) compared to the females (slope=-0.41, R²=0.22). One particular study found a 507 difference in motivating factors for adult physical activities amongst the sexes [22]. Another 508 study found that while males were motivated by mastery of physical activity, females were 509 motivated by the psychosocial wellbeing component of exercise [26]. Additionally, previous 510 studies have demonstrated that males were less likely to report depression than females, despite

511 more males completing suicide due to the gravity of their deteriorating mental health [27]. 512 However, we cannot ignore the potential biological differences between males and females and 513 the prevalence of depression. There is evidence that estrogen acting as a psycho-protective 514 component in the body, and the conversion of testosterone to estrogen in males mediates a 515 protective action throughout life. While estrogen levels fluctuate with the premenstrual cycle in 516 females, testosterone has a more consistent level in males [27]. Cognitive function results from 517 this cohort showed a slightly more rapid decline in females (slope=-0.1782, R²=0.06) compared 518 to males (slope=-0.0622, R²=0.01), but a low incidence of dementia reported in this cohort may 519 influence these findings.

520

521 Comparing Quality of Life Parameter Correlations

522 In a thorough investigation conducted by Yamada et al., cross-sectional studies of the data 523 unveiled significant correlations between measures of pain and fatigue/tiredness [29]. Although 524 the study's main focus was on the relationship between pain and tiredness symptoms over time in 525 people with musculoskeletal disorders, it is crucial to interpret these results in the context of the 526 larger body of research on the relationship between pain and fatigue. Strong evidence of a 527 relationship between pain and tiredness was found in our dataset; this relationship graphically 528 displayed in a heatmap. This numerical insight not only underscores the significance of our 529 study's specific analysis but also contributes valuable quantitative evidence to the broader body 530 of research affirming the intricate relationship between pain and fatigue. 531 According to Linton et al.'s analysis, there is a clear relationship between pain and depression,

532 which calls for a complex understanding of their interaction within the therapeutic framework

533 [30]. Within our dataset there was a significant relationship between pain interference and

534 depression. These results highlight the necessity of further research efforts to thoroughly 535 investigate this association, clarifying the importance for improving therapeutic approaches. 536 Fatigue or exhaustion is a widespread issue in both community and medical settings, and there is 537 a strong association with depression. The correlation between enhanced work performance and 538 improved energy underscores the importance of addressing fatigue in the context of depression. 539 In our study, an analysis of depression and tiredness/fatigue revealed a significant association 540 meriting the need for further investigation [31]. 541 542 Paterson et al.'s study of generalized physical activity and functional limitations demonstrated 543 that regular physical activity is associated with a reduced risk of functional limitations, 544 particularly in the older age group [32]. In a preclinical study of VCP disease, exercise training 545 in mice with the Arg155His Vcp variant found that there was an improvement with uphill 546 exercise [33]. Korb et al.'s recommendations of the standard of care for patients with VCP 547 disease acknowledges that exercise has a positive effect on individuals with FTD [34]. A recent 548 study on resistance respiratory exercise in subjects with VCP myopathy showed that the 549 maximum inspiratory pressure increased significantly over the 32 week course of the resistance 550 training compared to the baseline [35]. The effects of generalized exercise training however have 551 not been studied and is a significant unmet need because of the absence of clear guidelines on 552 exercise training in the VCP myopathy patient population. 553

554 Patient Perspective and Management of Care

555 Quality of life is imperative to navigating a patient's health. Treatment options are catered to

556 maximizing a patient's quality of life, and therefore understanding patient perspectives is integral

557 to optimizing patient care [36]. In chronic diseases of neurological or musculoskeletal 558 disabilities, it has been demonstrated that psychological impacts may lead to a decline in the 559 QOL of a patient [37-38]. Additionally, chronic illnesses like VCP disease may increase the 560 prevalence of depression. Routine management of chronic disease warrants depression 561 screenings and management of pain as patients progress through life with their diagnosis [38]. 562 To gain a better understanding of patient perspectives in VCP disease, we analyzed the responses 563 to better understand how fatigue, pain, and depression directly impacted their daily life. A 564 patient's pain level displayed a moderate negative correlation to both fatigue (-0.57) and how 565 often pain interfered with their enjoyment of life (-0.56). In other words, as pain level increased, 566 a patient was more likely to report being tired and having pain interfere with their enjoyment of 567 life. Interestingly, fatigue and pain interference have the same correlation to pain level 568 suggesting the significance of both pain and fatigue in the enjoyment of life. Moreover, a 569 significant percentage of VCP patients reported experiencing fatigue at high levels, with 76% 570 (51/66) reporting that they often or always felt tired and 88% (57/66) of symptomatic 571 participants reporting that their health often or always limits doing vigorous activities. A 572 correlation analysis between fatigue, pain inference, and depression further revealed a moderate 573 correlation between all three of these factors [pain inference and fatigue (0.63), fatigue and 574 depression (0.46), and pain inference and depression (0.41)], suggesting that these symptoms 575 may be interrelated and should be monitored throughout the life of a VCP patient. The inclusion 576 of a mental health section in the VCP care guidelines further demonstrates the importance of 577 including psychological health in a VCP patient's overall care plan [34]. 578

579

580 Limitations and Future Directions

581 Understanding the mechanisms of complex traits through genotype-phenotype comparisons can 582 be limiting because there can be multiple genetic and environmental factors that can contribute to 583 the differences. Understanding interactions between modifier genes and variants on the gene-of-584 interest, epigenetics, and environmental factors that lead to certain phenotypes are factors that 585 should be taken into consideration [21]. The phenotypic diversity of VCP disease is not 586 necessarily due to the specific types of VCP variants [8]. Patients with the same VCP variant 587 who are in the same family can present with different phenotypes and clinical manifestations. 588 Other environmental or genetic modifiers that have yet to be investigated [24]. Prior studies 589 have shown a correlation of the apolipoprotein-E (APOE4) allele as a potential VCP modifier 590 gene [39]. VCP patients with one or more APOE4 alleles had dementia as a phenotypic 591 characteristic. Based on these studies, modifier genes and potential interactions with VCP such 592 as APOE4, NF1, among others should be accounted for in future studies to better understand 593 their effects on phenotype along with VCP variants [39]. Our group has also indicated that the 594 R159C variant is associated with a lower incidence of PDB [16].

595

While the PROMs are very useful in understanding a patient's perspective of disease and monitoring their longitudinal progression, there are limitations to this data. Because PROMs are subjective, there are many parameters that can influence the subject's response. Depending on how patients have been feeling, even days leading up to the questionnaire, can influence their general perspective of how they answer the survey questions. Moreover, there can be variation in assessment on a day-to-day basis since the time period for this questionnaire is 7 days. In addition, every subject's idea of items such as "vigorous activities", "depression", "general health", and "pain" are subjective and based on their perception. In addition, participants have subjective levels of pain tolerance at baseline. Moreover, the progression of the disease does not have the same initial baseline for the participants, as the disease duration is unique for each participant. Therefore, progression is relative to the patient's disease progression. For a more complete disease understanding and natural history, PROMS should be complemented with clinical examination, diagnostic imaging, and clinical diagnosis.

609

610 Analyzing the patient-reported progression of VCP disease can provide great insight into its 611 clinical manifestations; however, more longitudinal data is needed. While we were able to 612 observe the overall trend in cognitive function, mobility, and pain in this study, only 17 613 participants reported unique results two or more times. most participants only reporting one data 614 entry. This limited our ability to report on an individual's reported change over time. Retrieving 615 additional data entries from existing participants will provide a better understanding of the 616 disease progression. In addition, including more pre-symptomatic participants with a VCP 617 disease variant will allow the monitoring of disease progression longitudinally. 618 Another limitation is that participants did not submit answers to all survey questions due to the 619 protocol management by the internal review board at Sanford Research. This protocol reviewed 620 by the review board at Sanford Research allows subjects the option to omit questions which they 621 do not feel comfortable answering. While this protocol may eliminate erroneous answers from 622 patients and increase overall registry enrollment, not having all answers completed leads to 623 challenges in conducting correlation analysis, including having to exclude some participants 624 from calculations entirely.

625

626	Increasing the sample size of the cohort to include statistically significant data in VCP genotype-
627	phenotype comparisons can help to analyze the progression in participants with other
628	comorbidities such as ALS, PDB, and peripheral neuropathy. This could provide better insight as
629	to how other conditions impact the severity of QOL symptoms amongst participants with VCP
630	disease. Moreover, collecting data for a longer period of time will allow for increased data
631	consistency and the monitoring of the long-term progression of VCP phenotypic manifestations.
632	As more responses are collected over time in the VCP CoRDS Registry, further data analysis can
633	be conducted, allowing for a longer span of time to understand the correlation of how QOL
634	changes over time with disease progression.
635	
636	Conclusion
637	Patient registries are valuable tools in improving clinical care and setting future research
637 638	Patient registries are valuable tools in improving clinical care and setting future research direction by including the patient voice, capturing natural history data, and elevating the QOL of
638	direction by including the patient voice, capturing natural history data, and elevating the QOL of
638 639	direction by including the patient voice, capturing natural history data, and elevating the QOL of patients. The VCP CoRDS Registry was found to be a valuable tool for monitoring the quality of
638 639 640	direction by including the patient voice, capturing natural history data, and elevating the QOL of patients. The VCP CoRDS Registry was found to be a valuable tool for monitoring the quality of life in patients with VCP disease. The results of this study could be a useful tool in monitoring
638 639 640 641	direction by including the patient voice, capturing natural history data, and elevating the QOL of patients. The VCP CoRDS Registry was found to be a valuable tool for monitoring the quality of life in patients with VCP disease. The results of this study could be a useful tool in monitoring the natural history progression of upper extremity function, lower extremity function, and
638 639 640 641 642	direction by including the patient voice, capturing natural history data, and elevating the QOL of patients. The VCP CoRDS Registry was found to be a valuable tool for monitoring the quality of life in patients with VCP disease. The results of this study could be a useful tool in monitoring the natural history progression of upper extremity function, lower extremity function, and cognitive function in the VCP patient population. This study indicates that patient-driven
638 639 640 641 642 643	direction by including the patient voice, capturing natural history data, and elevating the QOL of patients. The VCP CoRDS Registry was found to be a valuable tool for monitoring the quality of life in patients with VCP disease. The results of this study could be a useful tool in monitoring the natural history progression of upper extremity function, lower extremity function, and cognitive function in the VCP patient population. This study indicates that patient-driven registries such as CoRDS can be used to monitor disease progression in rare diseases on a global
 638 639 640 641 642 643 644 	direction by including the patient voice, capturing natural history data, and elevating the QOL of patients. The VCP CoRDS Registry was found to be a valuable tool for monitoring the quality of life in patients with VCP disease. The results of this study could be a useful tool in monitoring the natural history progression of upper extremity function, lower extremity function, and cognitive function in the VCP patient population. This study indicates that patient-driven registries such as CoRDS can be used to monitor disease progression in rare diseases on a global

647 Ethics Approval and Consent to Participate

648	Written informed consent was obtained from all individuals. This study was approved by the
649	University of California Irvine Institutional Review Board (IRB) (#2007-5832).
650	
651	Consent for Publication
652	Written informed consent was obtained from all the subjects included in the study. In the case of
653	deceased patients, they provided their consents prior to their demise.
654	
655	Authors' Contributions
656	Virginia Kimonis, Allison Peck: Conceptualization, methodology, resources, supervision,
657	validation, project administration, writing and funding acquisition.
658	Eiman Abdoalsadig: Investigation, writing - original draft, visualization, and validation.
659	Merwa Hamid: Investigation, writing - original draft, visualization, and validation.
660	Leepakshi Johar: Investigation, writing - original draft, and visualization.
661	All authors read and approved the final manuscript.
662	Competing Interests
663	The authors declare that they have no competing interests.
664	Funding
665	This work was supported by the Cure VCP Disease, Inc. and the Coordination of Rare Diseases at
666	Sanford (CoRDS) Research Institute
667	Availability of Data and Materials
668	The datasets generated during and/or analyzed during the current study are available_

- 669 from the corresponding author on reasonable request.
- 670 Acknowledgments

We thank the participants for their contribution to the study. Our gratitude extends to the Cure VCP Disease, Inc., Alyssa Mendel, and the Coordination of Rare Diseases at Sanford (CoRDS) Research Institute, Sioux Falls, S. Dakota for their support with the acquisition and management of registry data. We are grateful to Regina Im, Vu Luu, Mabel Tang, and Ryan Mahoney for their contribution to this work.

676

677 **References**

- [1] Kimonis VE, Kovach MJ, Waggoner B, Leal S, Salam A, Rimer L, et al. Clinical and
- 679 molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy
- and Paget disease of bone. Genet Med. 2000;2(4):232-41.
- 681 [2] Tucker WS, Jr., Hubbard WH, Stryker TD, Morgan SW, Evans OB, Freemon FR, et al. A
- new familial disorder of combined lower motor neuron degeneration and skeletal
- disorganization. Trans Assoc Am Physicians. 1982; 95:126-34.
- [3] Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, et al. Clinical
- delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four
- 686 families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal
- 687 dementia. Mol Genet Metab. 2001;74(4):458-75.
- [4] Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body
- myopathy associated with Paget disease of bone and frontotemporal dementia is caused by
- 690 mutant valosin-containing protein. Nat Genet. 2004;36(4):377-81.
- [5] Meyer H, Weihl CC. The VCP/p97 system at a glance: connecting cellular function to
- 692 disease pathogenesis. J Cell Sci. 2014;127(Pt 18):3877-83.

- [6] Pfeffer G, Lee G, Pontifex CS, Fanganiello RD, Peck A, Weihl CC, Kimonis V. Multisystem
- 694 Proteinopathy Due to VCP Mutations: A Review of Clinical Heterogeneity and Genetic
- 695 Diagnosis. Genes (Basel). 2022 May 27;13(6):963.
- [7] Rabinovich E, Kerem A, Frohlich KU, Diamant N, Bar-Nun S. AAA-ATPase p97/Cdc48p, a
- 697 cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol Cell
- 698 Biol. 2002;22(2):626-34.
- [8] Al-Obeidi E, Al-Tahan S, Surampalli A, Goyal N, Wang AK, Hermann A, et al. Genotype-
- phenotype study in patients with valosin-containing protein mutations associated with
- 701 multisystem proteinopathy. Clin Genet. 2018;93(1):119-25.
- 702 [9] Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, et al. TDP-43 accumulation in
- inclusion body myopathy muscle suggests a common pathogenic mechanism with
- frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008;79(10):1186-9.
- [10] Langston AL, Ralston SH. Management of Paget's disease of bone. Rheumatology
 (Oxford). 2004;43(8):955-9.
- [11] Hubbers CU, Clemen CS, Kesper K, Boddrich A, Hofmann A, Kamarainen O, et al.
- Pathological consequences of VCP mutations on human striated muscle. Brain. 2007;130(Pt
 2):381-93.
- 710 [12] Majounie E, Traynor BJ, Chio A, Restagno G, Mandrioli J, Benatar M, et al. Mutational
- analysis of the *VCP* gene in Parkinson's disease. Neurobiol Aging. 2012;33(1):209 e1-2.
- 712 [13] Nalbandian A, Donkervoort S, Dec E, Badadani M, Katheria V, Rana P, et al. The multiple
- faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's
- 714 disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci.
- 715 2011;45(3):522-31.

- 716 [14] Guyant-Maréchal, L., Laquerrière, A., Duyckaerts, C., Dumanchin, C., Bou, J., Dugny, F.,
- 717 Le Ber, I., Frébourg, T., Hannequin, D., & Campion, D. (2006). Valosin-containing protein gene
- 718 mutations: clinical and neuropathologic features. Neurology, 67(4), 644–651.
- 719 https://doi.org/10.1212/01.wnl.0000225184.14578.d3
- 720 [15] Cella, D., Lai, J. S., Nowinski, C. J., Victorson, D., Peterman, A., Miller, D., Bethoux, F.,
- Heinemann, A., Rubin, S., Cavazos, J. E., Reder, A. T., Sufit, R., Simuni, T., Holmes, G. L.,
- Siderowf, A., Wojna, V., Bode, R., McKinney, N., Podrabsky, T., Wortman, K., ... Moy, C.
- 723 (2012). Neuro-QOL: brief measures of health-related quality of life for clinical research in
- neurology. Neurology, 78(23), 1860–1867. https://doi.org/10.1212/WNL.0b013e318258f744
- 725 [16] Chan, N., Le, C., Shieh, P., Mozaffar, T., Khare, M., Bronstein, J., & Kimonis, V. (2012).
- 726 Valosin-containing protein mutation and Parkinson's disease. Parkinsonism & related disorders,
- 727 18(1), 107–109. https://doi.org/10.1016/j.parkreldis.2011.07.006
- [17] Baumhauer J. F. (2017). Patient-Reported Outcomes Are They Living Up to Their
- 729 Potential? The New England journal of medicine, 377(1), 6–9.
- 730 https://doi.org/10.1056/NEJMp1702978
- [18] Lasiter, L., Campbell, A., Basch, E., Hudgens, S., Stewart, M., Wu, J. J., Leahy, A. B., &
- Allen, J. (2020). Use of Patient-Reported Outcomes to Understand & Measure the Patient
- 733 Experience of Novel Cell and Gene Therapies. Therapeutic innovation & regulatory science,
- 734 54(6), 1566–1575. https://doi.org/10.1007/s43441-020-00184-6
- [19] Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, et al.
- 736 Clinical studies in familial VCP myopathy associated with Paget disease of bone and
- frontotemporal dementia. Am J Med Genet A. 2008;146A(6):745-57.

- 738 [20] Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body
- myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul Disord.
- 740 2009;19(5):308-15.
- [21] Mehta SG, Khare M, Ramani R, Watts GD, Simon M, Osann KE, et al. Genotype-
- phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone
- and/or frontotemporal dementia. Clin Genet. 2013;83(5):422-31.
- [22] Orgogozo, V., Morizot, B., & Martin, A. (2015). The differential view of genotype-
- phenotype relationships. Frontiers in genetics, 6, 179. https://doi.org/10.3389/fgene.2015.00179
- 746 [23] LoMauro, A., Gandossini, S., Russo, A., Diella, E., Pistininzi, C., Marchi, E., Pascuzzo, R.,
- 747 Vantini, S., Aliverti, A., & D'Angelo, M. G. (2021). Over three decades of natural history of
- ⁷⁴⁸ limb girdle muscular dystrophy type R1/2A and R2/2B: Mathematical modelling of a
- 749 multifactorial study. Neuromuscular disorders: NMD, 31(6), 489–497.
- 750 https://doi.org/10.1016/j.nmd.2021.02.018
- 751 [24] Murphy, A. P., Morrow, J., Dahlqvist, J. R., Stojkovic, T., Willis, T. A., Sinclair, C. D. J.,
- 752 Wastling, S., Yousry, T., Hanna, M. S., James, M. K., Mayhew, A., Eagle, M., Lee, L. E.,
- Hogrel, J. Y., Carlier, P. G., Thornton, J. S., Vissing, J., Hollingsworth, K. G., & Straub, V.
- (2019). Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial
- endpoints. Annals of clinical and translational neurology, 6(6), 1033–1045.
- 756 <u>https://doi.org/10.1002/acn3.774</u>
- 757 [25] Tang, L., Ma, Y., Liu, X., Chen, L., & Fan, D. (2019). Better survival in female SOD1-
- 758 mutant patients with ALS: A study of SOD1-related natural history. Translational
- 759 Neurodegeneration, 8(1). https://doi.org/10.1186/s40035-018-0142-8

- 760 [26] Salthouse T. A. (2011). Neuroanatomical substrates of age-related cognitive decline.
- 761 Psychological bulletin, 137(5), 753–784. https://doi.org/10.1037/a0023262
- 762 [27] Raz, N., Lindenberger, U., Rodrigue, K. M., Kennedy, K. M., Head, D., Williamson, A.,
- 763 Dahle, C., Gerstorf, D., & Acker, J. D. (2005). Regional brain changes in aging healthy adults:
- general trends, individual differences and modifiers. Cerebral cortex (New York, N.Y.: 1991),
- 765 15(11), 1676–1689. https://doi.org/10.1093/cercor/bhi044
- 766 [28] Fillingim R. B. (2017). Individual differences in pain: understanding the mosaic that makes
- 767 pain personal. Pain, 158 Suppl 1(Suppl 1), S11–S18.
- 768 https://doi.org/10.1097/j.pain.000000000000775
- [29] Yamada, K., Adams, H., Ellis, T., Clark, R., Sully, C., Lariviere, C., & Sullivan, M. J.
- 770 (2022). The temporal relation between pain and fatigue in individuals receiving treatment for
- chronic musculoskeletal pain. BMC musculoskeletal disorders, 23(1), 219.
- 772 https://doi.org/10.1186/s12891-022-05162-7
- [30] Linton, S. J., & Bergbom, S. (2011). Understanding the link between depression and
- pain. *Scandinavian journal of pain*, 2(2), 47–54. https://doi.org/10.1016/j.sjpain.2011.01.005
- [31] Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005). The many faces of fatigue in major
- depressive disorder. The international journal of neuropsychopharmacology, 8(1), 93–105.
- 777 https://doi.org/10.1017/S1461145704004729
- [32] Paterson, D. H., & Warburton, D. E. (2010). Physical activity and functional limitations in
- older adults: a systematic review related to Canada's Physical Activity Guidelines. The
- international journal of behavioral nutrition and physical activity, 7, 38.
- 781 https://doi.org/10.1186/1479-5868-7-38

- 782 [33] Nalbandian, A., Nguyen, C., Katheria, V., Llewellyn, K. J., Badadani, M., Caiozzo, V., &
- 783 Kimonis, V. E. (2013). Exercise training reverses skeletal muscle atrophy in an experimental
- 784 model of VCP disease. PloS one, 8(10), e76187. https://doi.org/10.1371/journal.pone.0076187
- [34] Korb, M., Peck, A., Alfano, L. N., Berger, K. I., James, M. K., Ghoshal, N., Healzer, E.,
- Henchcliffe, C., Khan, S., Mammen, P. P. A., Patel, S., Pfeffer, G., Ralston, S. H., Roy, B.,
- 787 Seeley, W. W., Swenson, A., Mozaffar, T., Weihl, C., Kimonis, V., & VCP Standards of Care
- 788 Working Group (2022). Development of a standard of care for patients with valosin-containing
- protein associated multisystem proteinopathy. Orphanet Journal of Rare Diseases, 17(1), 23.
- 790 https://doi.org/10.1186/s13023-022-02172-5
- [35] Halseth M, Mahoney R, Hsiou J, Jones HN, Kimonis V. Remote respiratory resistance
- respiratory function in individuals with VCP multisystem
- proteinopathy. Neuromuscul Disord. 2024 Jan; 34:68-74.
- [36] Sixma, H. J., Kerssens, J. J., Campen, C. V., & Peters, L. (1998). Quality of care from the
- patients' perspective: from theoretical concept to a new measuring instrument. Health
- respectations: an international journal of public participation in health care and health policy,
- 797 1(2), 82–95. https://doi.org/10.1046/j.1369-6513.1998.00004.x
- [37] Crombez, G., Veirman, E., Van Ryckeghem, D., Scott, W., & De Paepe, A. (2023). The
- reffect of psychological factors on pain outcomes: lessons learned for the next generation of
- 800 research. Pain reports, 8(6), e1112. https://doi.org/10.1097/PR9.00000000001112
- 801 [38] Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and Pain Comorbidity: A
- 802 Literature Review. Arch Intern Med. 2003;163(20):2433–2445.
- 803 doi:10.1001/archinte.163.20.2433

- 804 [39] Mehta, S. G., Watts, G. D., Adamson, J. L., Hutton, M., Umberger, G., Xiong, S., Ramdeen,
- 805 S., Lovell, M. A., Kimonis, V. E., & Smith, C. D. (2007). APOE is a potential modifier gene in
- 806 an autosomal dominant form of frontotemporal dementia (IBMPFD). Genetics in Medicine:
- 807 official journal of the American College of Medical Genetics, 9(1), 9–13.
- 808 <u>https://doi.org/10.1097/gim.0b013e31802d830d</u>

Supplemental Table 1	: Genotype-	-Phenotype	Compariso	1 Data of C	linical Fe	atures 238 S	Symptomatic	Patients in	n Differei	nt Variant G	roups																						
			Age of onset Age of onset								Age of o		Age of	onset				Age of	onset			Age of	onset		Age of onset								
			Myopa	thy		Paget's Disease of Bone					Dementia				Amyotrophic Lateral Sclerosis				Peripheral Neuropathy				Cardiomy	opathy		P	'arkinson'	s Disease		Cataracts			
Mutation group	N (%)	N (%)	Mean	Range	p-value	N (%)	Mean (yrs)	Range	p-value	N (%)	Mean (yrs)	Range	p-	N (%)	Mean	Range	p-	N (%)	Mean (yrs)	Range	p-	N (%)	Mean	Range	p-	N (%)	Mean	Range	p-value	N (%)	Mean (yrs)	Range	p-value
p.Arg155His	18 (36.0%)	17 (45.9%)	40.6 ± 8.2	27-59	0.12	3 (25.0%)	41.3 ± 10.0	30-49	0.61	2 (40.0%)	43.5 ± 4.9	40-47	0.23	2 (100.0%)	52.5 ± 9.2	46-59	1.0	4 (80.0%)	44.3 ± 13.1	27-59	0.99	1 (25.0%)	36.0	36	NA	1 (100.0%)	46.00	46	NA	3 (42.9%)	45.3 ± 11.9	37-59	0.78
p.Arg155Cys	8 (16.0%)	4 (10.8%)	39.3 ± 10.7	30-54	0.52	1 (8.3%)	33.0	33	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	2 (50.0%)	49.0 ± 7.1	44-54	0.47	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Arg159His	5 (10.0%)	1 (2.7%)	51.0	51	NA	0 (0.0%)	NA	NA	NA	2 (40.0%)	63.5 ± 10.6	56-71	0.39	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Arg93Cys	4 (8.0%)	3 (8.1%)	52.3 ± 6.8	47-60	0.14	3 (25.0%)	52.7 ± 7.4	47-61	0.21	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	3 (42.9%)	49.7 ± 9.3	42-60	0.73
p.Arg159Cys	4 (8.0%)	1 (2.7%)	50.0	50	NA	0 (0.0%)	NA	NA	NA	1 (20.0%)	50.0	50	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Arg191Gln	3 (6.0%)	3 (8.1%)	42.7 ± 4.6	40-48	0.89	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	1 (20.0%)	NA	NA	NA	1 (25.0%)	40	40	NA	0 (0.0%)	NA	NA	NA	1 (14.3%)	NA	NA	NA
p.Leu198Trp	2 (4.0%)	2 (5.4%)	38.0	38	NA	1 (8.3%)	38.0	38	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Gly97Glu	1 (2.0%)	1 (2.7%)	47.0	47	NA	1 (8.3%)	47.0	47	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Ile369Thr	1 (2.0%)	1 (2.7%)	61.0	61	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Arg95Gly	1 (2.0%)	1 (2.7%)	40.0	40	NA	1 (8.3%)	40.0	40	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Asn387Thr	1 (2.0%)	1 (2.7%)	58.0	58	NA	1 (8.3%)	58.0	58	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Gly128Ala	1 (2.0%)	1 (2.7%)	40.0	40	NA	1 (8.3%)	40.0	40	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
p.Gly782Ala	1 (2.0%)	1 (2.7%)	42.0	42	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA	0 (0.0%)	NA	NA	NA
	50 (100%)	37 (74.0%)	43.3 ± 8.8	27-60	0.87	12 (24.0%)	44.8 ± 9.3	30-61	0.99	5 (10.0%)	52.8 ± 11.7	40-71	1.0	2 (4.0%)	52.5 ± 9.2	46-59	1.0	5 (10.0%)	44.3 ± 13.1	27-59	0.99	4 (8.0%)	43.5 ± 7.7	36-54	1.0	1 (2.0%)	46.00	46	NA	7 (14.0%)	47.5 ± 9.8	37-60	1.0

Abbreviations: N number, ALS amyotrophic lateral sclerosis

NA indicates not applicable. No participants reported to have the corresponding symptoms in the phenotype categories.